Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Alabama
Clinical trial register · United States · industry-sponsored

Clinical Trials in Alabama, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9159 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Oct 2026, 03:16 UTC
9159
Studies in scope
industry-sponsored, all four open statuses
4974
Recruiting now
open to new participants
2202
Lead sponsors
across recruiting studies
Top states
California 5324 Florida 4464 Illinois 2496 Georgia 2367 Arizona 2252
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca67 Novartis Pharmaceuticals50 Eli Lilly and Company49 AbbVie44 Hoffmann-La Roche38
State
California5324 Florida4464 Illinois2496 Georgia2367 Arizona2252
All 51 states
Target enrolment
to

Trials with a site in Alabama

1301 of 9159 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Active, closed
ViiV Healthcare
Phase 1
69
Alabama, Florida, Illinois
2025-01-17
By invitation
An Investigational Study Examining the Efficacy of QbMobile in Treatment Monitoring in Individuals With ADHD
NCT07217977Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder (ADD)
Qbtech AB
Observational
175
Alabama, California, Florida, North Carolina, Texas
2025-01-15
Recruiting
Takeda
Phase 4
78
Alabama, Arizona, California, Delaware, Florida, Georgia, Illinois, Indiana
2025-01-14
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Alabama, Arizona, California, Colorado, Connecticut, Florida, Hawaii, Illinois
2025-01-13
Recruiting
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
NCT06011551Degenerative Disc Disease (DDD)
ReGelTec, Inc.
Not applicable
225
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Kansas, Louisiana
2025-01-13
Active, closed
Mylan Pharmaceuticals Inc
Phase 3
1,630
Alabama, Arizona, California, Florida, Georgia, Idaho, Kansas, Kentucky
2025-01-13
Recruiting
Novo Nordisk A/S
Phase 3
480
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-01-10
Recruiting
GlaxoSmithKline
Phase 3
1,840
Alabama, Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-01-10
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Alabama, Arizona, Arkansas, California, Florida, Illinois, Indiana, Kentucky
2025-01-08
Active, closed
Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular Access
NCT06712251Chronic Kidney Disease Requiring Hemodialysis, End Stage Renal Disease (ESRD)
Venova Medical
Not applicable
20
Alabama, California, Florida, Texas
2025-01-08
Recruiting
Pan-tumor MRD Study
NCT06605404Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Melanoma (Skin Cancer)
Paradigm Health
Observational
1,350
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-01-08
Recruiting
BioNTech SE
Phase 2/3
1,580
Alabama, Alaska, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-01-07
Active, closed
Pfizer
Phase 3
1,035
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-01-06
Active, closed
AstraZeneca
Phase 1/2
244
Alabama, California, Colorado, Florida, Georgia, Illinois, Iowa, Kentucky
2024-12-30
Recruiting
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
NCT06752668Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
DrugORX750
Centessa Pharmaceuticals (UK) Limited
Phase 2
248
Alabama, Arizona, California, Florida, Georgia, Louisiana, Massachusetts, Michigan
2024-12-23
Active, closed
ViiV Healthcare
Phase 2
229
Alabama, California, Florida, Illinois, Louisiana, Massachusetts, Michigan, Missouri
2024-12-20
Recruiting
Cytokinetics
Phase 3
1,800
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2024-12-19
Active, closed
Vertex Pharmaceuticals Incorporated
Observational
401
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2024-12-19
Recruiting
Sanofi
Phase 2
84
Alabama, California, Florida, Georgia, Illinois, Michigan, Minnesota, Nevada
2024-12-19
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
455
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-12-18
Active, closed
Cleerly, Inc.
Not applicable
1,000
Alabama, California, Colorado, Florida, Illinois, Iowa, Kentucky, Louisiana
2024-12-18
Active, closed
Celldex Therapeutics
Phase 2
131
Alabama, California, Florida, Georgia, Idaho, Illinois, Kentucky, Michigan
2024-12-18
Active, closed
Calliditas Therapeutics AB
Phase 4
60
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Kentucky
2024-12-17
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Alabama, Florida, Georgia, Illinois, Iowa, North Carolina, Pennsylvania, Texas
2024-12-17
Recruiting
GlaxoSmithKline
Phase 3
520
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Maine
2024-12-16
Recruiting
AbbVie
Phase 3
231
Alabama, Arizona, California, Florida, Georgia, Louisiana, Maryland, New York
2024-12-16
Recruiting
Janssen Research & Development, LLC
Phase 2
480
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-12-16
Recruiting
Basilea Pharmaceutica
Phase 3
450
Alabama, California, Georgia, Indiana, Kentucky, Maryland, Michigan, Minnesota
2024-12-11
Active, closed
Hoffmann-La Roche
Phase 3
350
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-12-11
Active, closed
Vicore Pharma AB
Phase 2
378
Alabama, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2024-12-09
Active, closed
Amgen
Phase 3
707
Alabama, California, Florida, Illinois, Indiana, Kentucky, Massachusetts, Michigan
2024-12-09
Recruiting
Teleflex
Observational
2,500
Alabama, California, Massachusetts
2024-12-08
Recruiting
Pfizer
Phase 3
2,330
Alabama, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-12-08
Recruiting
Corbus Pharmaceuticals Inc.
Phase 1/2
156
Alabama, Arizona, California, Colorado, Florida, Illinois, Minnesota, Nebraska
2024-12-04
Active, closed
ViiV Healthcare
Phase 3
326
Alabama, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2024-12-02
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,082
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-12-02
Active, closed
SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization
NCT06550024Osteo Arthritis Knee, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
CrannMed
Not applicable
89
Alabama, California, Florida, North Carolina, Virginia
2024-11-28
Recruiting
AstraZeneca
Phase 3
1,160
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-11-27
Active, closed
AbbVie
Observational
1,314
Alabama, Arizona, California, Florida, Kentucky, New York, Pennsylvania, Virginia
2024-11-26
Recruiting
Intra-Cellular Therapies, Inc.
Phase 3
160
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Massachusetts
2024-11-22
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
570
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Mississippi, New York
2024-11-21
Recruiting
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
DrugAlisertib
Puma Biotechnology, Inc.
Phase 2
225
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-11-19
Recruiting
Ensoma
Observational
60
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2024-11-18
Active, closed
Amgen
Phase 2
409
Alabama, California, Florida, Georgia, Illinois, Louisiana, Michigan, Montana
2024-11-07
Active, closed
Alnylam Pharmaceuticals
Phase 1/2
89
Alabama, California, Florida, Indiana, Massachusetts, Minnesota, Missouri, North Carolina
2024-11-07
Active, closed
Sanofi
Phase 2
556
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-11-07
Recruiting
Takeda
Phase 3
24
Alabama, Florida, Illinois, Indiana, Iowa, Michigan, Minnesota, Nevada
2024-11-06
Active, closed
Efficacy and Safety of VDPHL01 in Males With AGA
NCT06724614Androgenetic Alopecia, AGA, Male Pattern Baldness
DrugVDPHL01
Veradermics, Inc.
Phase 2/3
480
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2024-11-06
Recruiting
Chiesi Farmaceutici S.p.A.
Observational
100
Alabama, Georgia, Illinois, Iowa, Michigan, Virginia
2024-11-06
Active, closed
Angitia Biopharmaceuticals
Phase 2
379
Alabama, Georgia, New Mexico, Pennsylvania, Washington
2024-10-31
Recruiting
Abivax S.A.
Phase 2
212
Alabama, Arizona, California, Colorado, Florida, Illinois, Iowa, Massachusetts
2024-10-30
Recruiting
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
NCT06310031Cardiovascular Diseases, Heart Diseases, Heart Failure
BrioHealth Solutions, Inc.
Not applicable
780
Alabama, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas
2024-10-28
Active, closed
BioPorto Diagnostics
Observational
800
Alabama, California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, New Mexico
2024-10-28
Recruiting
Novartis Pharmaceuticals
Phase 3
354
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland
2024-10-24
Active, closed
Eli Lilly and Company
Phase 3
1,400
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-10-24
Recruiting
Shoulder Innovations Clinical Data Registry
NCT06754150Shoulder Arthroplasty
Shoulder Innovations
Observational
2,500
Alabama, California, Colorado, Florida, Georgia, Maryland, Massachusetts, Michigan
2024-10-23
Recruiting
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
NCT06511141Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer
Axonics, Inc.
Not applicable
150
Alabama, Arizona, California, Florida, Louisiana, Maryland, Michigan, Minnesota
2024-10-22
Active, closed
Eli Lilly and Company
Phase 2
252
Alabama, California, Florida, Hawaii, Illinois, Mississippi, Pennsylvania, Washington
2024-10-21
Active, closed
Pfizer
Phase 3
600
Alabama, Arizona, California, Colorado, Florida, Illinois, Kentucky, Maine
2024-10-21
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2
300
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Michigan
2024-10-18
Recruiting
Aptitude Medical Systems
Not applicable
1,000
Alabama, Louisiana
2024-10-17
Active, closed
Uniquity One (UNI)
Phase 2
184
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2024-10-16
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Alabama, California, Florida, Massachusetts, Michigan, Minnesota, Texas, Washington
2024-10-15
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2024-10-14
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 3
24
Alabama, Florida, Massachusetts, Michigan, Pennsylvania, Texas, Wisconsin
2024-10-14
Active, closed
Incyte Corporation
Phase 3
349
Alabama, Arizona, Arkansas, California, Florida, Illinois, Indiana, Michigan
2024-10-10
Active, closed
Ipsen
Phase 2
670
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Louisiana
2024-10-10
Active, closed
Gilead Sciences
Phase 3
609
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-09
Active, closed
Gilead Sciences
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-08
Active, closed
Vaxart
Phase 2
5,485
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-10-08
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2024-10-07
Recruiting
Eli Lilly and Company
Observational
6,250
Alabama
2024-10-07
Recruiting
AbbVie
Phase 2
488
Alabama, California, Florida, Kentucky, New York, Rhode Island, South Carolina, Texas
2024-10-07
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-10-04
Recruiting
SoniVie Inc.
Not applicable
261
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Illinois, Louisiana
2024-10-03
Recruiting
ALTO-100 in Bipolar Disorder With Depression (BD-D)
NCT06656416Bipolar Disorder I or II With a Major Depressive Episode
Alto Neuroscience
Phase 2
200
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-10-02
Recruiting
Ferring Pharmaceuticals
Phase 3
454
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2024-10-01
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 3
1,100
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-10-01
Active, closed
SIMPLAAFY Clinical Trial
NCT06521463Atrial Fibrillation, Stroke, Bleeding
Boston Scientific Corporation
Not applicable
1,857
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-10-01
Recruiting
Stemline Therapeutics, Inc.
Phase 3
4,220
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-09-27
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-09-26
Active, closed
Merus B.V.
Phase 3
699
Alabama, California, Delaware, District of Columbia, Florida, Georgia, Illinois, Kentucky
2024-09-25
Active, closed
ADVENT Post Approval Study
NCT06431815Paroxysmal Atrial Fibrillation
Boston Scientific Corporation
Observational
228
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Louisiana, Massachusetts
2024-09-25
Active, closed
Nocion Therapeutics
Phase 2
455
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-09-24
Active, closed
ModernaTX, Inc.
Phase 3
37,864
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2024-09-24
Recruiting
Autobahn Therapeutics, Inc.
Phase 2
230
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts
2024-09-20
Active, closed
Cerevance
Phase 3
330
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas
2024-09-20
Active, closed
Hoffmann-La Roche
Phase 3
400
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-09-17
Recruiting
Abbott Medical Devices
Not applicable
100
Alabama, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Minnesota
2024-09-11
Recruiting
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150Non-cystic Fibrosis Bronchiectasis
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Phase 2
284
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Indiana, Iowa
2024-09-11
Active, closed
AbbVie
Phase 3
496
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii
2024-09-10
Recruiting
Acorn Biolabs Inc.
Observational
500
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Michigan
2024-09-09
Active, closed
Takeda
Phase 3
2,099
Alabama, Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois
2024-09-04
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Alabama, California, Illinois, Iowa, Kentucky, Massachusetts, Missouri, North Carolina
2024-09-04
Recruiting
AbbVie
Phase 2
590
Alabama, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2024-09-04
Active, closed
Treace Medical Concepts, Inc.
Observational
92
Alabama, Florida, Missouri, Ohio, Texas
2024-09-04
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Idaho
2024-08-30
Active, closed
Celgene
Phase 2
95
Alabama, Alaska, Arizona, California, District of Columbia, Florida, Kansas, Minnesota
2024-08-30
Active, closed
Boehringer Ingelheim
Phase 3
8,371
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-08-30
Active, closed
argenx
Phase 2
33
Alabama, California, Illinois, Nebraska, North Carolina, Ohio, Virginia, Washington
2024-08-30
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
93
Alabama, Arizona, California, Florida, Massachusetts, Minnesota, Missouri, New Jersey
2024-08-26
Active, closed
Skye Bioscience, Inc.
Phase 2
136
Alabama, California, Connecticut, Georgia, Kentucky, Nebraska, Nevada, New Hampshire
2024-08-22
Recruiting
Sanofi
Phase 3
160
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas
2024-08-21
Active, closed
Gilead Sciences
Phase 2/3
675
Alabama, California, District of Columbia, Florida, Georgia, Michigan, Missouri, New Jersey
2024-08-20
Recruiting
Innova Vascular, Inc.
Not applicable
107
Alabama, Arizona, California, District of Columbia, Florida, Illinois, New York, North Carolina
2024-08-19
Recruiting
Novartis Pharmaceuticals
Phase 1/2
161
Alabama, Florida, Massachusetts, New York, North Carolina, Pennsylvania, Rhode Island, Texas
2024-08-15
Active, closed
Uniquity One (UNI)
Phase 2
182
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-08-14
Active, closed
Incyte Corporation
Phase 1
37
Alabama, California, Florida, Illinois, Kansas, Michigan, New York, Oregon
2024-08-08
Active, closed
Pfizer
Observational
450
Alabama, California, Florida, Iowa, Maryland, Massachusetts, Michigan, Minnesota
2024-08-07
Recruiting
AstraZeneca
Phase 3
1,018
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2024-08-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
3,000
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-08-05
Active, closed
GlaxoSmithKline
Phase 3
10,212
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas
2024-08-01
Recruiting
Axsome Therapeutics, Inc.
Phase 3
520
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-08-01
Recruiting
NovoCure GmbH
Phase 3
734
Alabama, Arizona, California, Florida, Illinois, Indiana, Kansas, Missouri
2024-07-31
Recruiting
PinkDx, Inc.
Observational
4,500
Alabama, California, Florida, Illinois, Indiana, Minnesota, Missouri, New York
2024-07-30
By invitation
Biohaven Therapeutics Ltd.
Phase 2
660
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-07-30
Active, closed
UCB Biopharma SRL
Phase 3
89
Alabama, California, Florida, Michigan, New York, Pennsylvania
2024-07-29
Active, closed
Uniquity One (UNI)
Phase 2
145
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-07-26
Recruiting
Janssen Research & Development, LLC
Phase 3
752
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-07-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
Alabama, Alaska, Arizona, California, Florida, Georgia, Louisiana, Nevada
2024-07-24
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
DrugsTislelizumab·Bevacizumab
BeOne Medicines
Phase 1/2
630
Alabama, Arizona, California, Illinois, New York, Pennsylvania, Tennessee, Texas
2024-07-23
Recruiting
Daiichi Sankyo
Phase 1/2
123
Alabama, Arizona, California, Florida, Illinois, Michigan, Minnesota, New Hampshire
2024-07-22
Recruiting
TG Therapeutics, Inc.
Observational
2,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-07-22
Recruiting
QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry
NCT06517810Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
SeaStar Medical
Observational
50
Alabama, California, Colorado, Georgia, Illinois, Michigan, Ohio, Pennsylvania
2024-07-19
Active, closed
Celldex Therapeutics
Phase 3
976
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-07-19
Recruiting
Bristol-Myers Squibb
Phase 1/2
224
Alabama, California, Connecticut, Georgia, Illinois, Kansas, Maryland, Massachusetts
2024-07-17
Recruiting
Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT
NCT05399537Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury (AKI)
Vantive Health LLC
Phase 3
40
Alabama, California, Florida, Georgia, Michigan, Ohio, Pennsylvania, South Carolina
2024-07-12
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Alabama, California, Colorado, Connecticut, Florida, Illinois, Kansas, Louisiana
2024-07-12
Active, closed
Celldex Therapeutics
Phase 3
963
Alabama, California, Colorado, Florida, Idaho, Illinois, Indiana, Kentucky
2024-07-11
Active, closed
UCB Biopharma SRL
Phase 3
70
Alabama, New Jersey, North Carolina
2024-07-10
By invitation
Apnimed
Phase 3
1,280
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2024-07-03
Active, closed
Novartis Pharmaceuticals
Phase 2
155
Alabama, California, Florida, Georgia, Indiana, Louisiana, Michigan, Ohio
2024-07-02
Recruiting
GlaxoSmithKline
Phase 1
675
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New York
2024-07-02
Recruiting
HPC Offered for PRESERVE Expansion
NCT07145411Bone Marrow Transplant (BMT)
Ossium Health, Inc.
Observational
10
Alabama, Michigan, Ohio, Tennessee
2024-06-27
Active, closed
AbbVie
Phase 3
1,400
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2024-06-27
Recruiting
Tempus AI
Observational
500
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-06-26
Active, closed
Merus B.V.
Phase 3
621
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2024-06-25
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2024-06-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-06-24
Active, closed
Sanofi
Phase 2
185
Alabama, Arizona, California, Colorado, Connecticut, Florida, Indiana, Massachusetts
2024-06-20
Active, closed
Celgene
Phase 3
850
Alabama, Alaska, Arizona, California, Florida, Georgia, Illinois, Iowa
2024-06-19
Recruiting
Beam Therapeutics Inc.
Phase 1/2
192
Alabama, Massachusetts, South Carolina
2024-06-19
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Alabama, California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2024-06-17
Active, closed
AbbVie
Phase 3
184
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2024-06-14
Recruiting
Gilead Sciences
Phase 1/2
250
Alabama, Connecticut, Georgia, Kentucky, Massachusetts, New Jersey, New York, Ohio
2024-06-12
Recruiting
UniQure Biopharma B.V.
Phase 1/2
12
Alabama, Arizona, California, Florida, Kansas, Maryland, Massachusetts, Michigan
2024-06-12
Recruiting
Takeda
Phase 4
60
Alabama, Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky
2024-06-12
Active, closed
Teoxane SA
Not applicable
20
Alabama, New York
2024-06-11
Recruiting
LEO Pharma
Phase 3
195
Alabama, Arkansas, California, Florida, Georgia, Michigan, Oklahoma, Oregon
2024-06-10
Active, closed
GlaxoSmithKline
Phase 4
303
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Michigan
2024-06-06
Recruiting
UniQure Biopharma B.V.
Phase 1/2
20
Alabama, California, Georgia, Illinois, Minnesota, New York, Ohio, Pennsylvania
2024-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-06-05
Active, closed
Amgen
Phase 3
563
Alabama, California, Connecticut, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2024-06-05
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Alabama, Arizona, California, Colorado, Delaware, District of Columbia, Florida, Iowa
2024-06-03
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
89bio, Inc.
Phase 3
762
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-05-24
Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C
DrugsBBO-10203·Pembrolizumab
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
350
Alabama, California, Colorado, Connecticut, Illinois, Kansas, Maryland, Michigan
2024-05-22
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2024-05-21
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2024-05-20
Active, closed
AbbVie
Phase 3
421
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana
2024-05-19
Recruiting
Intra-Cellular Therapies, Inc.
Phase 3
384
Alabama, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-05-14
Active, closed
Sanofi
Phase 3
1,541
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2024-05-08
Active, closed
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
NCT06267391Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes
Endogenex, Inc.
Not applicable
350
Alabama, California, Florida, Illinois, Iowa, Maryland, Minnesota, New Jersey
2024-05-01
Active, closed
Eli Lilly and Company
Phase 3
10,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-04-30
Recruiting
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
NCT06164730Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
DrugVERVE-102
Verve Therapeutics, Inc.
Phase 1
85
Alabama, California, Florida, Indiana, North Carolina, Pennsylvania, Texas, Washington
2024-04-30
Recruiting
Eli Lilly and Company
Phase 3
510
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2024-04-29
Recruiting
CSL Behring
Phase 2/3
3,110
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-04-27
Active, closed
AbbVie
Phase 2/3
2,701
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2024-04-26
Active, closed
Amgen
Phase 3
111
Alabama, Arizona, California, Delaware, Florida, Georgia, Indiana, Maryland
2024-04-22
Recruiting
Takeda
Phase 4
50
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas
2024-04-18
Active, closed
Bristol-Myers Squibb
Phase 3
44
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-04-17
Recruiting
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
NCT06228326Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer
DrugsKB707·Docetaxel·Keytruda·Pembrolizumab
Krystal Biotech, Inc.
Phase 1/2
250
Alabama, Arizona, California, Florida, Indiana, Louisiana, Michigan, Ohio
2024-04-17
Active, closed
GlaxoSmithKline
Phase 4
1,358
Alabama, Arkansas, California, Delaware, Florida, Illinois, Louisiana, Maine
2024-04-16
Recruiting
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
NCT05908331In-Stent Restenosis, Cardiovascular Diseases, Coronary Artery Disease
Concept Medical Inc.
Not applicable
492
Alabama, Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Minnesota
2024-04-16
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2024-04-16
Active, closed
Celldex Therapeutics
Phase 2
140
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2024-04-12
Recruiting
AstraZeneca
Phase 3
3,850
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-04-12
Active, closed
Shape Memory Medical, Inc.
Not applicable
180
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Maine
2024-04-05
Recruiting
A Study of Sovilnesib in Subjects With Ovarian Cancer
NCT06084416High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability
Volastra Therapeutics, Inc.
Phase 1
150
Alabama, Arkansas, California, Georgia, Maryland, Massachusetts, New York, Oklahoma
2024-04-04
Active, closed
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
DrugPirfenidone
Avalyn Pharma Inc.
Phase 2
398
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-04-03
Active, closed
Artiva Biotherapeutics, Inc.
Phase 1
51
Alabama, Arizona, California, Florida, Iowa, North Carolina, Texas
2024-04-03
Active, closed
Novo Nordisk A/S
Phase 3
673
Alabama, Arkansas, California, Florida, Georgia, Illinois, Kentucky, Maryland
2024-04-01
Active, closed
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
NCT06235151Prostate Cancer, Prostate Adenocarcinoma
Curium US LLC
Phase 3
439
Alabama, Arkansas, California, District of Columbia, Florida, Illinois, Indiana, Iowa
2024-04-01
Recruiting
Corbus Pharmaceuticals Inc.
Phase 1/2
348
Alabama, California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Nebraska
2024-04-01
Active, closed
AstraZeneca
Phase 3
2,554
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-03-29
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Alabama, Arizona, California, Florida, Georgia, Louisiana, Massachusetts, Minnesota
2024-03-29
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
120
Alabama, California, Colorado, Connecticut, Kansas, Massachusetts, Missouri, New Jersey
2024-03-28
Active, closed
Study of JK07 in Patients With Chronic Heart Failure
NCT06369298Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Salubris Biotherapeutics Inc
Phase 2
282
Alabama, Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois
2024-03-28
Recruiting
Italfarmaco
Phase 3
220
Alabama, California, Colorado, Maryland, New York, North Carolina, Ohio, Oregon
2024-03-26
Recruiting
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
NCT06163430Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia
DrugHS-10382
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2
330
Alabama, Arizona, California, Colorado, Florida, Georgia, New York, North Carolina
2024-03-26
Recruiting
Molecure S.A.
Phase 2
96
Alabama, Kansas, Maryland, Minnesota, Ohio, Pennsylvania, South Carolina
2024-03-21
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
230
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-03-21
Recruiting
Supernus Pharmaceuticals, Inc.
Phase 4
286
Alabama, Arkansas, California, Colorado, Florida, Georgia, Indiana, Kentucky
2024-03-19
Recruiting
Translational Sciences, Inc.
Phase 2
300
Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois
2024-03-18
Active, closed
Eli Lilly and Company
Phase 3
320
Alabama, Arizona, California, Florida, Georgia, Idaho, Kansas, Montana
2024-03-15
By invitation
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
NCT05932615Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder
Abbott Medical Devices
Not applicable
1,500
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2024-03-15
Active, closed
Regeneron Pharmaceuticals
Phase 2
1,005
Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois
2024-03-13
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-03-13
Recruiting
AtriCure, Inc.
Observational
10,000
Alabama, Arkansas, California, Colorado, District of Columbia, Florida, Indiana, Kansas
2024-03-11
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New Jersey
2024-03-07
Active, closed
Eli Lilly and Company
Phase 3
17,300
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-03-05
Active, closed
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
NCT06239116Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Rhythm Pharmaceuticals, Inc.
Phase 1/2
111
Alabama, Illinois, Massachusetts, Tennessee, Texas, Utah
2024-03-05
Active, closed
AstraZeneca
Phase 3
594
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Kentucky
2024-03-04
Active, closed
Sanofi
Phase 3
464
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana
2024-02-29
Active, closed
A Study in Patients With Mixed Dyslipidemia
NCT06497127Mixed Dyslipidemia
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
145
Alabama, Florida, Georgia, Illinois, Kansas, New York, Oklahoma, Texas
2024-02-28
Recruiting
Novartis Pharmaceuticals
Phase 3
1,444
Alabama, Alaska, Arizona, Arkansas, California, Colorado, District of Columbia, Florida
2024-02-28
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Alabama, Arizona, California, Florida, Georgia, Massachusetts, Minnesota, Nebraska
2024-02-22
Recruiting
AstraZeneca
Phase 3
5,250
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-02-21
Active, closed
Eli Lilly and Company
Phase 3
1,250
Alabama, California, Colorado, Florida, Georgia, Hawaii, Idaho, Indiana
2024-02-21
Recruiting
Sonavex, Inc.
Not applicable
304
Alabama, Arizona, Florida, Illinois, Kansas, Massachusetts, Michigan, New Jersey
2024-02-21
Recruiting
Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
NCT04706013Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Medicure
Phase 3
15
Alabama, California, Colorado, Massachusetts, North Carolina, Ohio
2024-02-16
Recruiting
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma
DrugT-Bren
SystImmune Inc.
Phase 1
280
Alabama, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2024-02-09
Active, closed
Boehringer Ingelheim
Phase 3
428
Alabama, Arizona, California, Missouri, Nevada, New York, North Carolina, Ohio
2024-02-09
Recruiting
InSilico Medicine Hong Kong Limited
Phase 2
40
Alabama, Arizona, California, Florida, North Carolina, Oklahoma, Pennsylvania, South Carolina
2024-02-08
Recruiting
Puma Biotechnology, Inc.
Phase 2
120
Alabama, California, Colorado, District of Columbia, Florida, Illinois, Indiana, Maryland
2024-02-08
Recruiting
Pfizer
Phase 3
492
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas
2024-02-08
Active, closed
Lantheus Medical Imaging
Phase 4
274
Alabama, California, Georgia, Iowa, Maryland, Massachusetts, Michigan, Missouri
2024-02-08
Active, closed
Eikon Therapeutics
Phase 2
70
Alabama, Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois
2024-02-06
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Alabama, Alaska, Arizona, California, Georgia, Illinois, Indiana, Kansas
2024-02-05
Active, closed
ZILRETTA in Subjects With Shoulder Osteoarthritis
NCT06269705Glenohumeral Osteoarthritis
Pacira Pharmaceuticals, Inc
Phase 3
150
Alabama, Arizona, California, District of Columbia, Florida, Idaho, Kansas, Louisiana
2024-02-05
Active, closed
ReCode Therapeutics
Phase 2
128
Alabama, Arizona, California, Colorado, Georgia, Massachusetts, New York, North Carolina
2024-02-01
Active, closed
Registry of the Patient Experience for Carpal Tunnel Release
NCT06071468Carpal Tunnel Syndrome, CTS
Sonex Health, Inc.
Observational
1,424
Alabama, Arizona, Connecticut, Florida, Indiana, Massachusetts, Michigan, Minnesota
2024-01-26
Active, closed
AbbVie
Observational
427
Alabama, Arizona, California, District of Columbia, Florida, Illinois, Louisiana, Massachusetts
2024-01-24
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Alabama, California, Colorado, Connecticut, Florida, Massachusetts, New York, Tennessee
2024-01-23
By invitation
Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion
NCT06000319Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis
DrugNatural Matrix Protein (NMP) Fibers
Induce Biologics USA Inc.
Observational
200
Alabama
2024-01-04
Active, closed
Currax Pharmaceuticals
Phase 4
8,600
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-01-03
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Alabama, California, Florida, Georgia, Illinois, New York, Texas, Virginia
2023-12-29
Active, closed
Boston Scientific Corporation
Not applicable
484
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2023-12-28
Active, closed
Sanofi
Phase 3
943
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-27
Active, closed
Merck Sharp & Dohme LLC
Phase 2
147
Alabama, Alaska, Arkansas, California, Florida, Georgia, Washington
2023-12-26
Recruiting
Clarity Pharmaceuticals Ltd
Phase 3
383
Alabama, Arizona, Arkansas, California, Florida, Illinois, Indiana, Kansas
2023-12-21
Recruiting
Eli Lilly and Company
Phase 3
1,264
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-21
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Massachusetts
2023-12-20
Recruiting
AstraZeneca
Phase 3
1,145
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois
2023-12-14
Active, closed
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
DrugCretostimogene Grenadenorepvec
CG Oncology, Inc.
Phase 3
367
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-14
Active, closed
Sanofi
Phase 3
1,655
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Indiana
2023-12-13
Active, closed
Hoffmann-La Roche
Phase 3
1,050
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Kentucky, Maine
2023-12-11
Recruiting
Zenith® Fenestrated+ Clinical Study
NCT04875429Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
Cook Research Incorporated
Not applicable
105
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Maryland
2023-12-08
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2023-12-07
Active, closed
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153Neovascular Age-related Macular Degeneration (nAMD)
DrugAflibercept
Alcon Research
Phase 1/2
139
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Alabama, Alaska, Arizona, California, Connecticut, District of Columbia, Florida, Georgia
2023-12-06
Active, closed
AstraZeneca
Phase 3
760
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2023-12-04
Recruiting
GIE Medical
Phase 3
198
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2023-12-01
Recruiting
Akero Therapeutics, Inc
Phase 3
1,650
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-01
Active, closed
Incyte Corporation
Phase 3
467
Alabama, California, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2023-11-29
By invitation
Evaluation of the GORE® Ascending Stent Graft
NCT05800743Aortic Aneurysm, Thoracic, Pseudoaneurysm, Aortic Dissection, Aorta; Lesion
W.L.Gore & Associates
Not applicable
370
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-11-28
Active, closed
Genentech, Inc.
Phase 1
65
Alabama, Connecticut, New York, Ohio, Pennsylvania, Tennessee
2023-11-27
Active, closed
Incyte Corporation
Phase 3
450
Alabama, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2023-11-27
Recruiting
AstraZeneca
Phase 3
625
Alabama, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2023-11-23
Recruiting
Hoffmann-La Roche
Phase 3
1,100
Alabama, Arkansas, Florida, Georgia, Idaho, Indiana, Kentucky, Louisiana
2023-11-22
Active, closed
SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening
NCT06120205Hpv, HPV 16 Infection, HPV Infection, High Risk HPV
Teal Health, Inc.
Not applicable
870
Alabama, California, Colorado, Connecticut, Louisiana, Maryland, Massachusetts, Missouri
2023-11-20
Active, closed
Renibus Therapeutics, Inc.
Observational
200
Alabama, Indiana, Michigan, Texas
2023-11-18
Active, closed
The PEERLESS II Study
NCT06055920Pulmonary Embolism
Inari Medical
Not applicable
1,200
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Michigan
2023-11-17
Active, closed
Gilead Sciences
Phase 2
253
Alabama, California, District of Columbia, Georgia, Massachusetts, New Jersey, New York, North Carolina
2023-11-17
Recruiting
Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
NCT06157177Sciatica Acute, Lumbar Spinal Stenosis
DrugMetaxalone
Primus Pharmaceuticals
Phase 4
50
Alabama, California, Florida, Georgia, Michigan, New Mexico, North Carolina, Ohio
2023-11-15
Active, closed
AstraZeneca
Phase 3
1,902
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2023-11-14
Active, closed
Akero Therapeutics, Inc
Phase 3
700
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana
2023-11-10
Active, closed
Xentria, Inc.
Phase 1/2
32
Alabama, Colorado, Florida, Illinois, Iowa, Maryland, Michigan, Minnesota
2023-11-10
Active, closed
AstraZeneca
Phase 3
1,835
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2023-11-07
Active, closed
Bristol-Myers Squibb
Phase 2
227
Alabama, Colorado, Florida, Illinois, Indiana, Missouri, New Jersey, New York
2023-11-07
Active, closed
Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant
NCT06163404Nasal Septal Deviation, Nasal Airway Obstruction
Spirair, Inc
Not applicable
102
Alabama, California, Kentucky, Louisiana, New York, Pennsylvania, Washington
2023-11-01
Recruiting
United Therapeutics
Phase 3
698
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2023-10-30
Recruiting
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
NCT05953090Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva
Stratpharma AG
Not applicable
2,000
Alabama, California, Florida, Georgia, Nevada, North Carolina, South Carolina, Tennessee
2023-10-30
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2023-10-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-10-25
Active, closed
Cortex
Not applicable
400
Alabama, Arizona, California, Colorado, Florida, Georgia, Michigan, New York
2023-10-23
Active, closed
AskBio Inc
Phase 2
150
Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Kansas
2023-10-20
Active, closed
Grace Therapeutics Inc.
Phase 3
100
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2023-10-20
Recruiting
Protara Therapeutics
Phase 2
38
Alabama, Arkansas, Colorado, District of Columbia, Florida, New York, Ohio, Oregon
2023-10-18
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Alabama, Arizona, California, Florida, Indiana, Kansas, Kentucky, Maryland
2023-10-13
Active, closed
Ipsen
Phase 3
759
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-10-12
Recruiting
AbbVie
Phase 3
1,500
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2023-10-11
Active, closed
Clinuvel, Inc.
Phase 3
200
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Louisiana, Michigan
2023-10-11
Recruiting
Sanofi
Phase 3
180
Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Maryland
2023-10-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-10-09
Active, closed
AstraZeneca
Phase 3
5,511
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida
2023-10-05
By invitation
Biogen
Phase 3
306
Alabama, Arizona, California, Michigan, Missouri, North Carolina, Ohio, Pennsylvania
2023-10-03
Recruiting
DalCor Pharmaceuticals
Phase 3
2,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2023-10-03
Recruiting
Octapharma
Phase 3
30
Alabama, California, Kentucky, Pennsylvania, Texas, Virginia
2023-10-01
Active, closed
Ipsen
Phase 3
751
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Maryland
2023-09-29
Active, closed
Astria Therapeutics, Inc.
Phase 2
56
Alabama, Arizona, Arkansas, California, Maryland, Massachusetts, Missouri, Ohio
2023-09-26
Recruiting
AstraZeneca
Phase 3
800
Alabama, Arizona, Arkansas, California, Georgia, Illinois, Indiana, Louisiana
2023-09-22
Recruiting
Protara Therapeutics
Phase 2
131
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Louisiana
2023-09-15
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2023-09-14
Recruiting
ProDa BioTech, LLC
Phase 1
46
Alabama
2023-09-14
Recruiting
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
NCT06034275Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
Vincerx Pharma, Inc.
Phase 1
36
Alabama, Ohio, Tennessee, Texas, Washington
2023-09-13
Recruiting
Biotest
Phase 3
590
Alabama, Arizona, California, Georgia, Maryland, Massachusetts, Michigan, Missouri
2023-09-09
Recruiting
IC-8 Apthera IOL New Enrollment Post Approval Study
NCT06060041Cataract, Presbyopia, Posterior Capsule Opacification
Bausch & Lomb Incorporated
Observational
435
Alabama, California, Florida, Illinois, Indiana, Kansas, Michigan, Nebraska
2023-09-08
Active, closed
In8bio Inc.
Phase 1/2
4
Alabama, Florida, Kentucky, Ohio
2023-09-08
Recruiting
Gilead Sciences
Phase 3
402
Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Kentucky
2023-09-07
By invitation
Disc Medicine, Inc
Phase 2/3
230
Alabama, California, Florida, Massachusetts, New York, North Carolina, Ohio, Pennsylvania
2023-08-31
Active, closed
Janssen Research & Development, LLC
Phase 3
420
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana
2023-08-31
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Alabama, California, Florida, Georgia, Indiana, Kentucky, New Jersey, New York
2023-08-31
Active, closed
Cytokinetics
Phase 3
500
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois
2023-08-31
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
2,772
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-08-30
Active, closed
Bavarian Nordic
Phase 3
715
Alabama, Arizona, Florida, Illinois, Kansas, Kentucky, Missouri, Nevada
2023-08-30
Recruiting
AstraZeneca
Phase 3
231
Alabama, Arizona, Arkansas, California, Georgia, Maryland, Massachusetts, Michigan
2023-08-24
Recruiting
Pfizer
Phase 2
340
Alabama, Arizona, California, Colorado, Florida, Indiana, Maryland, Michigan
2023-08-22
Active, closed
ViiV Healthcare
Phase 2
185
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2023-08-17
Recruiting
Glaukos Corporation
Phase 2
84
Alabama, California, Colorado, Florida, Georgia, Indiana, Michigan, Missouri
2023-08-17
Active, closed
Emalex Biosciences Inc.
Phase 3
150
Alabama, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-08-16
Active, closed
AstraZeneca
Phase 3
142
Alabama, California, District of Columbia, Oregon
2023-08-16
Recruiting
Sumitomo Pharma Switzerland GmbH
Phase 3
1,000
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-08-14
Active, closed
Hoffmann-La Roche
Phase 3
459
Alabama, California, Florida, Georgia, Idaho, Illinois, Massachusetts, Nevada
2023-08-08
Recruiting
Incyte Corporation
Observational
1,500
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2023-08-01
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Alabama, California, Massachusetts, Nevada, New Jersey, New York, Ohio, Tennessee
2023-07-31
Recruiting
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
NCT05762107Type 1 Diabetes Mellitus With Hypoglycemia
Zucara Therapeutics Inc.
Phase 2
186
Alabama, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-07-28
Active, closed
Hoffmann-La Roche
Phase 2
21
Alabama, Connecticut, Florida, Massachusetts, Michigan
2023-07-24
Recruiting
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
NCT05879367Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
DrugsDFMO·Eflornithine·Temodar·Temozolomide
Orbus Therapeutics, Inc.
Phase 1
66
Alabama, Michigan, New York, North Carolina, Ohio, Rhode Island, Texas, Utah
2023-07-24
Recruiting
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
NCT05850234Relapsed/Refractory Multiple Myeloma
DrugAZD0120
AstraZeneca
Phase 1/2
232
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2023-07-20
Active, closed
Mineralys Therapeutics Inc.
Phase 3
1,076
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2023-07-14
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-07-11
Active, closed
Incyte Corporation
Phase 2
247
Alabama, California, Florida, Georgia, Illinois, Michigan, New York, North Carolina
2023-07-11
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Alabama, California, Colorado, Florida, Illinois, Indiana, Iowa, Minnesota
2023-07-06
Recruiting
DynamiCure Biotechnology
Phase 1
320
Alabama, Arizona, Colorado, Connecticut, Florida, Maryland, Massachusetts, Minnesota
2023-06-28
Active, closed
Hoffmann-La Roche
Phase 3
2,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana
2023-06-28
Active, closed
Cognition Therapeutics
Phase 2
540
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Indiana
2023-06-28
Active, closed
OncoC4, Inc.
Phase 3
630
Alabama, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Kansas
2023-06-28
Active, closed
Alumis Inc
Phase 2
408
Alabama, California, Florida, Georgia, Missouri, Nevada, New Jersey, New Mexico
2023-06-26
Active, closed
AbbVie
Phase 3
1,328
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2023-06-21
Recruiting
TG Therapeutics, Inc.
Phase 3
800
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2023-06-13
Active, closed
Neurogene Inc.
Phase 3
33
Alabama, California, Colorado, Florida, Illinois, Maryland, Massachusetts, New York
2023-06-13
Active, closed
NEUROMARK Registry Study
NCT05937308Chronic Rhinitis
Neurent Medical
Not applicable
150
Alabama, California, Florida, Kentucky, Texas, Utah, Virginia
2023-06-12
Active, closed
Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis
NCT05835895Osteoarthritis, Knee, Osteo Arthritis Knee, Knee Osteoarthritis
Genascence Corporation
Phase 1
67
Alabama, California, Florida, Missouri, North Carolina, Pennsylvania
2023-06-12
Recruiting
LifeNet Health
Observational
100
Alabama, California, Virginia
2023-06-06
Active, closed
Pelvic Fixation and Fusion During Multilevel Spinal Surgery
NCT05640908Spinal Fusion, Deformity of Spine
SI-BONE, Inc.
Observational
200
Alabama, Colorado, Michigan, Minnesota, New York, North Carolina, Texas
2023-06-05
Active, closed
Sapience Therapeutics
Phase 1
130
Alabama, California, Colorado, Louisiana, Massachusetts, Michigan, New York, North Carolina
2023-06-05
By invitation
AbbVie
Phase 3
650
Alabama, Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas
2023-06-05
Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3
DrugSafusidenib
Nuvation Bio Inc.
Phase 3
365
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-06-05
Active, closed
MapLight Therapeutics
Phase 2
120
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Michigan, Missouri
2023-06-01
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Illinois, Indiana
2023-06-01
Active, closed
Cullinan Therapeutics Inc.
Phase 1
90
Alabama, California, Georgia, Massachusetts, New Jersey, Texas
2023-05-31
Active, closed
Amgen
Phase 3
509
Alabama, Alaska, Arkansas, California, Illinois, Indiana, Iowa, Kentucky
2023-05-31
Recruiting
Vanda Pharmaceuticals
Phase 4
100
Alabama, Arkansas, Colorado, Georgia, North Carolina, Ohio, Washington
2023-05-24
Active, closed
Lantheus Medical Imaging
Observational
500
Alabama, Arkansas, California, Michigan, Missouri, Nebraska, Pennsylvania, Tennessee
2023-05-22
Recruiting
Takeda
Phase 3
240
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Maryland
2023-05-16
Recruiting
Varian, a Siemens Healthineers Company
Not applicable
134
Alabama, California, Missouri, Ohio
2023-05-14
By invitation
G7 Freedom Constrained Vivacit-E Liners
NCT05587244Osteoarthritis, Hip, Rheumatoid Arthritis, Non-Union Fracture, Trochanteric Fractures
Zimmer Biomet
Not applicable
202
Alabama, California, Florida, New Jersey, Ohio, Tennessee, Texas, Utah
2023-05-08
By invitation
Guided Therapeutics
Not applicable
400
Alabama, Georgia, Michigan, Virginia
2023-05-05
Recruiting
Intra-Cellular Therapies, Inc.
Phase 3
470
Alabama, California, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri
2023-05-02
Recruiting
AbbVie
Phase 3
450
Alabama, Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas
2023-05-01
Active, closed
Rhythm Pharmaceuticals, Inc.
Phase 3
143
Alabama, California, Colorado, Florida, Illinois, Iowa, Massachusetts, Minnesota
2023-04-26
Active, closed
AstraZeneca
Phase 2
294
Alabama, California, Kansas, New York
2023-04-24
Recruiting
GlaxoSmithKline
Phase 3
138
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2023-04-24
Active, closed
Hoffmann-La Roche
Phase 2
199
Alabama, California, Georgia, Maryland, Tennessee, Texas
2023-04-21
Active, closed
Novartis Pharmaceuticals
Phase 3
288
Alabama, California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland
2023-04-21
Active, closed
Hansa Biopharma AB
Observational
64
Alabama, California, Illinois, Maryland, Massachusetts, Missouri, New Jersey, New York
2023-04-21
Active, closed
Karyopharm Therapeutics Inc
Phase 3
257
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2023-04-18
Recruiting
SeaStar Medical
Not applicable
339
Alabama, Arizona, California, Colorado, Florida, Georgia, Iowa, Kentucky
2023-04-17
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2023-04-11
Recruiting
Takeda
Phase 2/3
500
Alabama, California, Colorado, Florida, Georgia, Massachusetts, Michigan, North Carolina
2023-04-05
Active, closed
ModernaTX, Inc.
Phase 1
482
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2023-04-05
Active, closed
Sanofi
Phase 2
999
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2023-04-03
Recruiting
AstraZeneca
Phase 3
4,300
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2023-03-31
Active, closed
In-Office Clinical Study of the Solo+ TTD
NCT05741333Ear Infection, Otitis Media
AventaMed DAC
Not applicable
66
Alabama, California, Kentucky, Pennsylvania, South Carolina
2023-03-30
Recruiting
Iovance Biotherapeutics, Inc.
Phase 3
670
Alabama, California, Colorado, Florida, Illinois, Kansas, Kentucky, Maryland
2023-03-30
Recruiting
Tvardi Therapeutics, Incorporated
Phase 1/2
193
Alabama, California, Colorado, District of Columbia, Florida, Maryland, Michigan, Missouri
2023-03-23
Active, closed
Merck Sharp & Dohme LLC
Phase 3
641
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Missouri, New Jersey
2023-03-17
Active, closed
Thoraflex Hybrid and Relay Extension Post-Approval Study
NCT05639400Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm
Vascutek Ltd.
Observational
352
Alabama, California, Colorado, Connecticut, District of Columbia, Illinois, Indiana, Maryland
2023-03-17
Active, closed
AbbVie
Phase 3
520
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Iowa
2023-03-15
By invitation
Eli Lilly and Company
Phase 3
333
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Idaho, Illinois
2023-03-09
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2023-03-09
Active, closed
Kardium Inc.
Not applicable
549
Alabama, Arkansas, California, Florida, Maryland, Michigan, New York, Ohio
2023-03-09
Recruiting
Takeda
Phase 3
160
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Iowa
2023-03-06
Recruiting
BeiGene
Observational
111
Alabama, California, Mississippi, Nevada
2023-03-03
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2023-03-02
Active, closed
Novo Nordisk A/S
Phase 3
7,101
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2023-03-01
Recruiting
Eli Lilly and Company
Phase 3
595
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2023-02-27
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
DrugsTovorafenib·Carboplatin
Day One Biopharmaceuticals, Inc.
Phase 3
418
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-02-27
Active, closed
Gilead Sciences
Phase 2
400
Alabama, California, Florida, Illinois, Louisiana, Michigan, Virginia, Washington
2023-02-21
Active, closed
DBV Technologies
Phase 3
600
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2023-02-21
By invitation
Ardelyx
Phase 3
150
Alabama, California, Florida, Illinois, Indiana, Maine, Minnesota, Nebraska
2023-02-17
Recruiting
Xenon Pharmaceuticals Inc.
Phase 3
160
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Hawaii
2023-02-14
Active, closed
Kite, A Gilead Company
Phase 3
300
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2023-02-10
Recruiting
Caribou Biosciences, Inc.
Phase 1
50
Alabama, Colorado, Florida, Kentucky, New Jersey, New York, North Carolina, Ohio
2023-02-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Alabama, California, Florida, Georgia, Louisiana, Michigan, Minnesota, New York
2023-02-06
Active, closed
Hoffmann-La Roche
Phase 2
301
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Iowa
2023-02-03
Active, closed
Novo Nordisk A/S
Phase 3
47
Alabama, California, Colorado, District of Columbia, Idaho, Minnesota
2023-02-01
Recruiting
MYLUNG Consortium Part 3: Observational Study
NCT05885698Carcinoma, Non-Small-Cell Lung
US Oncology Research
Observational
7,500
Alabama, Arizona, Colorado, Florida, Illinois, Maryland, Minnesota, New York
2023-01-30
Recruiting
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
NCT05685433Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Valencia Technologies Corporation
Not applicable
200
Alabama, Arkansas, California, Florida, Georgia, Illinois, Iowa, Kansas
2023-01-26
Active, closed
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304Ischemic Stroke, Systemic Embolism
AtriCure, Inc.
Not applicable
6,573
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2023-01-25
Active, closed
Stemline Therapeutics, Inc.
Phase 1/2
435
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois
2023-01-24
Active, closed
Alumis Inc
Phase 2
165
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2023-01-17
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2023-01-16
Active, closed
Bristol-Myers Squibb
Phase 3
516
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-01-12
Active, closed
Daiichi Sankyo
Phase 3
1,170
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland
2023-01-11
Active, closed
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugIMGN151
AbbVie
Phase 1
256
Alabama, California, Colorado, Florida, Illinois, Massachusetts, Michigan, Mississippi
2023-01-11
Active, closed
Bristol-Myers Squibb
Phase 3
606
Alabama, California, Florida, Georgia, Idaho, Maryland, Massachusetts, Minnesota
2023-01-10
Active, closed
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
NCT05322590Metastatic Colorectal Carcinoma, Neuropathy
Bexion Pharmaceuticals, Inc.
Phase 1/2
195
Alabama, California, Florida, Iowa, Kentucky, Louisiana, New York, Ohio
2023-01-09
Recruiting
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
NCT05658575Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis
DrugDapansutrile
Olatec Therapeutics, Inc.
Phase 2/3
300
Alabama, Arizona, California, Florida, Georgia, Illinois, Kentucky, Michigan
2023-01-06
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana
2023-01-02
Recruiting
Proteocyte Diagnostics Inc.
Observational
180
Alabama, California, Minnesota, Texas
2023-01-01
Active, closed
Hoffmann-La Roche
Phase 3
1,290
Alabama, Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana
2022-12-29
By invitation
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
NCT05396105Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 2/3
150
Alabama, Arkansas, California, Colorado, Maryland, Massachusetts, Michigan, Missouri
2022-12-28
Recruiting
Anthos Therapeutics, Inc.
Phase 3
2,500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2022-12-27
Recruiting
Greenwich LifeSciences, Inc.
Phase 3
2,250
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-12-16
Active, closed
Amgen
Phase 3
7,297
Alabama, Alaska, Arizona, California, Colorado, Connecticut, District of Columbia, Florida
2022-12-14
Recruiting
AstraZeneca
Phase 3
3,527
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2022-12-13
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Alabama, California, New York, Virginia
2022-12-13
Recruiting
Gilead Sciences
Phase 3
1,514
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-12-12
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-12-09
Active, closed
Celcuity Inc
Phase 3
701
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2022-12-08
Active, closed
Bellus Health Inc. - a GSK company
Phase 3
997
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2022-12-05
Active, closed
Pfizer
Phase 1
148
Alabama, Arkansas, California, Florida, Louisiana, Massachusetts, Michigan, New Jersey
2022-11-30
Active, closed
Shanghai Henlius Biotech
Phase 3
200
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana
2022-11-18
Recruiting
Hoffmann-La Roche
Phase 1/2
65
Alabama, California, Maryland, Massachusetts, Missouri, New York, Ohio
2022-11-16
Active, closed
SoniVie Inc.
Not applicable
25
Alabama, Arkansas, Connecticut, Illinois, Minnesota, New York, North Carolina, South Carolina
2022-11-11
Active, closed
Novartis Pharmaceuticals
Phase 2
34
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2022-11-11
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
822
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2022-11-08
Recruiting
Advenchen Pharmaceuticals, LLC.
Phase 2
80
Alabama, Florida, Illinois, Missouri, Ohio
2022-11-01
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Alabama, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana
2022-11-01
Active, closed
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
NCT05284747Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
DrugsRepatha·Evolocumab
Amgen
Phase 4
6,019
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2022-10-26
Recruiting
Arcus Biosciences, Inc.
Phase 1
362
Alabama, California, Florida, Georgia, Kentucky, Louisiana, Maryland, Massachusetts
2022-10-26
Recruiting
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
DrugsPF-08046054·Keytruda·Pembrolizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
714
Alabama, California, Iowa, Michigan, Ohio, Texas, Utah, Virginia
2022-10-25
Active, closed
Abbott Atrial Fibrillation Post Approval Study
NCT05434650Atrial Arrhythmia, Atrium; Fibrillation, Atrial Tachycardia
Abbott Medical Devices
Observational
200
Alabama, Arkansas, California, Georgia, Louisiana, Massachusetts, Michigan, Mississippi
2022-10-21
Recruiting
Bristol-Myers Squibb
Phase 1/2
260
Alabama, Maryland, Massachusetts, New Jersey, New York
2022-10-18
Active, closed
Eli Lilly and Company
Phase 3
377
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Idaho, Illinois
2022-10-18
Active, closed
RNS System LGS Feasibility Study
NCT05339126Epilepsy, Lennox Gastaut Syndrome, Lennox-Gastaut Syndrome, Intractable, Seizures
NeuroPace
Phase 2
24
Alabama, California, Georgia, Massachusetts, New York
2022-10-04
Active, closed
Eli Lilly and Company
Phase 3
8,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-10-04
Active, closed
Janssen Research & Development, LLC
Phase 1
196
Alabama, California, Massachusetts, New York, North Carolina, Texas
2022-10-04
Active, closed
Q32 Bio Inc.
Phase 2
102
Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Maryland
2022-09-30
Active, closed
PharmaEssentia
Phase 2
91
Alabama, California, Connecticut, District of Columbia, Georgia, Indiana, Kentucky, Louisiana
2022-09-29
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Alabama, Connecticut, Florida, Kansas, Kentucky, Missouri, New York, Oklahoma
2022-09-27
Active, closed
Hoffmann-La Roche
Phase 3
122
Alabama, California, Colorado, District of Columbia, Massachusetts, Minnesota, New York, Ohio
2022-09-27
Recruiting
Pfizer
Phase 2/3
389
Alabama, Connecticut, Florida, Georgia, Illinois, Louisiana, Michigan, Mississippi
2022-09-22
Active, closed
AstraZeneca
Phase 3
594
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Mississippi
2022-09-15
Recruiting
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
NCT05519449Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
DrugsJANX007·Darolutamide
Janux Therapeutics
Phase 1
272
Alabama, Arizona, California, Connecticut, Florida, Illinois, Maryland, Minnesota
2022-09-15
Active, closed
Biogen
Phase 2/3
450
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2022-09-13
Active, closed
Exelixis
Phase 3
901
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2022-09-07
By invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
DrugTreprostinil
United Therapeutics
Phase 3
1,850
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2022-09-06
Active, closed
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
DrugSonrotoclax
BeOne Medicines
Phase 1/2
125
Alabama, Indiana, Louisiana, Maryland, New Jersey, Texas
2022-09-05
Recruiting
Genelux Corporation
Phase 3
186
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Michigan
2022-08-31
Active, closed
Beam Therapeutics Inc.
Phase 1/2
15
Alabama, Arizona, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri
2022-08-30
Active, closed
Hoffmann-La Roche
Phase 3
139
Alabama, California, Colorado, District of Columbia, Florida, Maryland, Massachusetts, Michigan
2022-08-30
Recruiting
Acrivon Therapeutics
Phase 2
350
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2022-08-29
Active, closed
Madrigal Pharmaceuticals, Inc.
Phase 3
845
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2022-08-26
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
410
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, New York
2022-08-23
Active, closed
Sanofi
Phase 2/3
1,856
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-08-22
Active, closed
Spine BioPharma, Inc
Phase 3
417
Alabama, Arizona, California, Florida, Georgia, Idaho, Indiana, Kansas
2022-08-19
Active, closed
Genmab
Phase 2
184
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-08-17
Active, closed
Novo Nordisk A/S
Phase 3
412
Alabama, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Idaho
2022-08-10
Active, closed
Bausch Health Americas, Inc.
Phase 3
466
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2022-08-03
Recruiting
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
NCT02397668Tricuspid Valve Disease
Corvivo Cardiovascular, Inc.
Not applicable
78
Alabama, Indiana, Maryland, Ohio
2022-08-01
Active, closed
Eli Lilly and Company
Phase 4
780
Alabama, California, Connecticut, Florida, Georgia, Indiana, Iowa, Kentucky
2022-08-01
Recruiting
Boston Scientific Corporation
Phase 1
36
Alabama, California, Florida, Illinois, Maryland, Missouri, New York, Texas
2022-07-30
Recruiting
Janssen Research & Development, LLC
Phase 1/2
225
Alabama, California, District of Columbia, Florida, Maryland, Michigan, Mississippi, New York
2022-07-29
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-07-22
Active, closed
PureTech
Phase 2
240
Alabama, California, Connecticut, Florida, Georgia, Indiana, Kansas, North Carolina
2022-07-22
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Alabama, California, Florida, Georgia, Louisiana, Michigan, Nevada, New York
2022-07-14
Recruiting
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
NCT05475925LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
DrugDibotatug
Dren Bio
Phase 1/2
200
Alabama, California, Connecticut, Florida, Massachusetts, New York, Ohio, Pennsylvania
2022-07-13
Active, closed
Novartis Pharmaceuticals
Phase 3
610
Alabama, Alaska, California, Connecticut, District of Columbia, Florida, Illinois, Indiana
2022-07-08
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
529
Alabama, Arizona, California, Florida, Georgia, Illinois, Kansas, Missouri
2022-06-30
Recruiting
BioRestorative Therapies
Phase 2
99
Alabama, California, Colorado, Florida, New York, North Carolina, Ohio, Oklahoma
2022-06-30
Recruiting
Alkermes, Inc.
Phase 3
220
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-06-30
Active, closed
Cloudbreak Therapeutics, LLC
Phase 3
660
Alabama, Arizona, California, Florida, Kentucky, Nevada, South Dakota, Texas
2022-06-30
Active, closed
Cogent Biosciences, Inc.
Phase 2
237
Alabama, Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts
2022-06-27
Active, closed
CooperVision, Inc.
Not applicable
900
Alabama, California, Florida, Illinois, Indiana, Kansas, Massachusetts, Minnesota
2022-06-25
Recruiting
Ferring Pharmaceuticals
Phase 1/2
39
Alabama, California, Maryland
2022-06-23
Recruiting
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114Non-Small Cell Lung Cancer
Tempus AI
Observational
1,200
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois
2022-06-22
Recruiting
Priothera SAS
Phase 3
366
Alabama, Arizona, California, Colorado, Florida, Georgia, Iowa, Kansas
2022-06-16
Recruiting
Neurona Therapeutics
Phase 3
88
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois
2022-06-16
Active, closed
Bayer
Observational
4,613
Alabama, Arizona, Arkansas, California, Florida, Georgia, Hawaii, Illinois
2022-06-13
Recruiting
Telios Pharma, Inc.
Phase 1/2
70
Alabama, Ohio, Texas
2022-06-09
Active, closed
THIO Sequenced With Cemiplimab in Advanced NSCLC
NCT05208944Carcinoma, Non-Small-Cell Lung
DrugsThiotepa·Cemiplimab
Maia Biotechnology
Phase 2
227
Alabama, New Jersey
2022-06-08
Active, closed
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
NCT04835428Vertebral Compression Fracture, Compression Fracture, Vertebral Compression
AgNovos Healthcare, LLC
Not applicable
408
Alabama, Arizona, Florida, Illinois, Kansas, Louisiana, Massachusetts, New York
2022-05-31
Recruiting
Dimerix Bioscience Pty Ltd
Phase 3
286
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2022-05-30
Active, closed
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Phase 2
56
Alabama, Michigan, Pennsylvania
2022-05-27
Active, closed
Artivion Inc.
Not applicable
115
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts
2022-05-27
Recruiting
Electra Therapeutics Inc.
Phase 2/3
156
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Maryland, New York
2022-05-19
Active, closed
ALTERRA Post-Approval Study
NCT05378386Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation
Edwards Lifesciences
Observational
150
Alabama, Arkansas, California, Colorado, Florida, Illinois, Massachusetts, Missouri
2022-05-12
Recruiting
Varian, a Siemens Healthineers Company
Not applicable
125
Alabama, Arkansas, California, Pennsylvania, Texas
2022-05-03
Active, closed
Sanofi
Phase 3
104
Alabama, California, Georgia, Illinois, New York, Texas, Utah, Virginia
2022-05-03
Active, closed
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755Moderate Aortic Valve Stenosis
Medtronic Cardiovascular
Not applicable
650
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Kentucky
2022-04-27
Recruiting
Cogent Biosciences, Inc.
Phase 3
482
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Iowa
2022-04-14
Active, closed
Protagonist Therapeutics, Inc.
Phase 3
293
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2022-04-11
Active, closed
Janssen Research & Development, LLC
Phase 1/2
235
Alabama, California, Colorado, Florida, Illinois, Indiana, Kentucky, Louisiana
2022-04-11
Active, closed
Bausch Health Americas, Inc.
Phase 3
524
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-04-07
Active, closed
Delfi Diagnostics Inc.
Observational
11,935
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2022-04-07
By invitation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Alabama, California, Colorado, Florida, Georgia, Massachusetts, Michigan, New York
2022-04-05
Active, closed
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
NCT05256290Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer
Black Diamond Therapeutics, Inc.
Phase 1/2
200
Alabama, Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Kansas
2022-03-31
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 2/3
522
Alabama, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia
2022-03-30
Recruiting
4D-710 in Adult Patients With Cystic Fibrosis
NCT05248230Cystic Fibrosis Lung
4D Molecular Therapeutics
Phase 2
30
Alabama, Arizona, California, Colorado, Florida, Illinois, Kansas, Maryland
2022-03-29
Active, closed
AstraZeneca
Phase 3
760
Alabama, Arizona, California, Georgia, Maryland, New Mexico, New York, Tennessee
2022-03-28
Recruiting
AbbVie
Phase 3
768
Alabama, Arizona, California, Florida, Georgia, Hawaii, Illinois, Indiana
2022-03-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Alabama, California, Florida, Indiana, Massachusetts, Michigan, Mississippi, Pennsylvania
2022-03-24
By invitation
Long-Term Follow-up Study
NCT05332054Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Caribou Biosciences, Inc.
Observational
150
Alabama, Arizona, California, Colorado, Florida, Georgia, Iowa, Kentucky
2022-03-16
By invitation
Global Utilization And Registry Database for Improved preservAtion of doNor Livers
NCT05082077Liver Diseases, Liver Dysfunction, Liver Transplant Disorder, Liver Transplant Rejection
Paragonix Technologies
Observational
2,000
Alabama, California, Florida, Georgia, Maryland, Massachusetts, Nebraska, North Carolina
2022-03-15
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Iowa
2022-03-15
Active, closed
Sanofi
Phase 3
122
Alabama, California, Florida, Georgia, New York, Ohio, Pennsylvania, Texas
2022-03-11
Active, closed
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
DrugFintepla
Zogenix, Inc.
Phase 3
87
Alabama, California, Colorado, District of Columbia, Georgia, Massachusetts, Michigan, North Carolina
2022-03-08
Active, closed
Novartis Pharmaceuticals
Phase 4
136
Alabama, Arizona, California, Florida, Idaho, Louisiana, Maryland, Massachusetts
2022-03-02
Recruiting
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 2
310
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2022-02-17
Active, closed
BioMarin Pharmaceutical
Phase 1/2
44
Alabama, Arizona, California, Colorado, Kansas, Maryland, Mississippi, Missouri
2022-02-15
Recruiting
Cordio Medical
Observational
500
Alabama, California, Florida, Georgia, Illinois, Kansas, Kentucky, Louisiana
2022-02-11
Active, closed
NewAmsterdam Pharma
Phase 3
9,541
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2022-02-07
Recruiting
Assessment of CCM in HF With Higher Ejection Fraction
NCT05064709Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
Impulse Dynamics
Not applicable
1,500
Alabama, Arizona, California, Connecticut, Florida, Georgia, Indiana, Iowa
2022-02-03
Active, closed
Genentech, Inc.
Phase 2
320
Alabama, Alaska, Arizona, California, Colorado, Delaware, Florida, Iowa
2022-02-01
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-01-19
Active, closed
Bristol-Myers Squibb
Phase 2
19
Alabama
2022-01-17
Rows per page Showing 501–1000 of 1301
Previous 1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 October 2026. https://priyalifescience.com/clinical-trials-usa/state/alabama?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,159 studies in total at the last sync on 22 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,301 of those studies with a site in Alabama.

How many clinical trials are recruiting in Alabama?

673 of the 1,301 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:16 UTC sync. A further 12 have not yet opened recruitment, 582 are active but closed to new participants, and 34 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.